"SoluBest has successfully advanced its technology in a critically important area of medicine. This promises to enhance patient outcomes through innovative and improved drug delivery. Now, with Michael Sheckler joining our talented team, we are confident that his added value will allow us to realize that promise in short order," said SoluBest Board Chairman Ronnie Hershman, M.D.
"I'm excited to have the opportunity to lead SoluBest to the next level of growth and commercialization. I share the passion of our Board and shareholders to bring our state-of-the-art technology to the pharmaceutical market in order to provide solubility-enhancing formulations for our partners' currently marketed and pipeline molecules," commented Mr. Sheckler.
SoluBest is a clinical stage company developing proprietary nanoformulation-based improvements of existing compounds and compounds in development.
The company applies its Solumer(TM) technology to poorly soluble or insoluble drugs which have not achieved their therapeutic potential due to delivery and/or compliance deficiencies.
The Company's proprietary solubilization technology is versatile and is widely applicable to numerous off-patent (or soon to be off-patent) drugs and new chemical entities (NCE's).
A significant advantage of the technology stems from its use of readily available equipment for a process consisting of a few simple steps - making scale-up safe, robust, rapid and inexpensive.
For more information, visit http://www.solubest.com.
|SOURCE SoluBest Ltd.|
Copyright©2008 PR Newswire.
All rights reserved